Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring
Expert Review of Clinical Pharmacology · 2026
DOI: 10.1080/17512433.2026.2632931 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Michele B Daly und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Branch, Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Anticoagulants, Chelating Agents, Doxycycline. Die Arbeit nennt 38 Literaturangaben. Gefördert von: CDC intramural funds and CDC contracts.
Abstract (Originalsprache)
BACKGROUND: Doxycycline post-exposure prophylaxis is recommended for men who have sex with men at high risk for sexually transmitted infections. Accurate doxycycline measures ensure consistent evaluation of adherence and efficacy. RESEARCH DESIGN AND METHODS: Participants received 200 mg doxycycline (blood collected in citrate [n = 20] or heparin [n = 14] tubes). Ex vivo analyses compared exogenous doxycycline spiked into blood from matched donors collected in citrate and heparin (n = 8) or EDTA and heparin (n = 9). Plasma doxycycline was quantified with liquid chromatography-tandem mass spectrometry and reported as geometric mean [95% CI]. RESULTS: After dosing, plasma doxycycline AUC24-72 h from citrate blood (17.07 µg/mL*hr [13.89-20.99]) was 3-times lower than heparin blood (54.57 [44.18-67.40]). Similarly, reduced plasma doxycycline was observed when drug was spiked into citrate (0.062 µg/mL [0.059-0.065]) versus heparin blood (0.084 µg/mL [0.077-0.092]) from matched donors (p = 0.0002). EDTA blood, also showed significantly lower plasma doxycycline (0.052 µg/mL [0.049-0.054]) than heparin blood (0.078 µg/mL [0.071-0.084]) (p < 0.0001). CONCLUSIONS: Chelating anticoagulants significantly reduce plasma doxycycline concentrations, likely through disruption of doxycycline-metal ion complexes and increased drug partitioning in red blood cells. Pharmacologically focused doxycycline research should prioritize blood collection in non-chelating anticoagulants or apply a correction factor if chelating anticoagulants are used. CLINICAL TRIAL REGISTRATION: NCT04860505, NCT05853120, and NCT06545656.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory Branch, Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
- 4ES Corporation, San Antonio, TX, USA.
- Oak Ridge Institute for Science and Education, Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
- Hope Clinic, Emory University, Atlanta, GA, USA.
Förderung
- CDC intramural funds and CDC contracts
Zitieren
APA
Daly, M. B., Spandau, M., Edwards, T. E., Dinh, C., Fountain, J., Dienhart, J. A., Conway-Washington, C., Kelley, C., Heneine, W., & Haaland, R. (2026). Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2632931
Vancouver
Daly MB, Spandau M, Edwards TE, Dinh C, Fountain J, Dienhart JA, et al. Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2632931
BibTeX
@article{Daly2026,
author = {Daly, Michele B and Spandau, Micah and Edwards, Tiancheng E and Dinh, Chuong and Fountain, Jeffrey and Dienhart, Jeannette A and Conway-Washington, Christopher and Kelley, Colleen and Heneine, Walid and Haaland, Richard},
title = {Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
doi = {10.1080/17512433.2026.2632931}
}
EUVIMED